臓器チップ (Organ-On-Chip) の世界市場：将来展望
Global Organ-On-Chip Market - 2019-2026
|出版日||ページ情報||英文 130-180 Pages
|臓器チップ (Organ-On-Chip) の世界市場：将来展望 Global Organ-On-Chip Market - 2019-2026|
|出版日: 2019年02月01日||ページ情報: 英文 130-180 Pages||
当レポートでは、世界の臓器チップ (Organ-On-Chip：生体機能チップ) 市場について分析し、市場の基本構造および最新情勢、全体的な市場動向の見通し (今後9年間分)、モデル別・エンドユーザー別および地域別の詳細動向、主な市場促進・抑制要因、市場競争構造、主要企業のプロファイル・事業戦略などについて調査しております。
Organ-on-chip is a multi-channel 3-D micro fluid cell culture ship which stimulates activities, mechanisms, physiological responses of entire organs. These micro devices are translucent, they provide a window to watch inner workings of human organs. This technology is being used to develop a whole pipeline of human organs-on-chip such as lung, gut, liver, heart, skin, bone marrow, pancreas, kidney and even a system that mimics the blood brain barrier. These organ-on-chip help pharmaceutical companies in replacing animal cells, comparison studies between humans and animals, the study of the toxicity of drugs and cosmetics, developing vaccines and drugs to counter bioterrorism threats, etc.,
The global organ-on-chip market was worth $XX billion in 2018 and is forecasted to reach $XX billion by 2026, at a CAGR of XX% during the forecast period.
The provision of research funds grants is considered as the key driver for the progress in the development of OOC devices and also positively impacts its market growth globally
In 2017, NCATS awarded a research grant of $2 million to Emulate, Inc., to use its human Brain-Chip model and develop a fully automated research platform, to conduct experiments on the International Space Station.
In 2017, In 2017, NCATS and its NIH collaborators funded an estimated $15 million in the fiscal year 2017 to fund 13 awards for the 'Tissue Chips for Disease Modeling and Efficacy Testing initiative.'
The surge in demand for organ-on-chip devices in the healthcare industry is expected to boost the growth of the global organ-on-chip market. Real-time imaging, in-vitro analysis of biochemical, and genetic & metabolic activities of living cells in functional tissues are some of the applications of organ-on-chip devices in the industry.
Major factors hindering the global organ-on-chip market are the high cost of devices because of the high manufacturing cost associated with complex manufacturing techniques.
Global organ-on-chip market is segmented by model and end users. Model type includes Liver-On-chip model, Lung-on-chip model, Heart-on-chip model, Kidney-on-chip model, Tumor models, Custom & Multi-organ-on-Chip models, and others, end users includes pharmaceutical companies, research organizations, and others
Rise in mortality rate due to an increase in the incidence of liver diseases such as hepatitis B, is expected to propel the demand for the liver-on-chip microfluidic model. Additionally, the surge in demand for liver-on-chip devices for drug screening is expected to fuel market growth.
The global organ-on-chip market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
North America dominate the global organ-on-chip due to a surge in adoption of organs-on-chips over 2D and 3D cell cultures. Furthermore, rise in demand for organ-on-chip (OOCs) in drug screening, especially in the U.S., the rise in R&D initiatives and increase in a number of key players of OOCs in North America are expected to fuel the growth of the market in the coming years.
On April 11, 2017, FDA announced a multi-year research and development agreement with a company called Emulate Inc. to test the company's "Organs-on-Chips" technology in laboratories at the agency's Center for Food Safety and Applied Nutrition.
Collaborative partnerships among the key players for research and development of advanced technology in the field of organ-on-chip and new product launches are driving the global organ-on-chip market.
In May 2018, Emulate, Inc. has formed a collaborative partnership with AstraZeneca's Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization.
In May 2018, CN Bio Innovations globally launched an organ-on-a-chip device that allows scientists to test potential drugs on living human organ models.
In October 2017, InSphero AG and Charles River Laboratories International, Inc. announced a partnership for the development of 3D InSight™ PDX Microtissues and expansion of in vitro oncology services.
In September 2017, AxoSim Technologies received a USD 1.7 million grant to expand its research aimed at fixing issues in pharmaceutical development.
Major market players in the Organ-on-chip market are CN Innovations Holdings Limited, Emulate, Inc., Axosim Technologies LLC, CN Bio Innovations, Kirkstall Limited, Insphero Ag, Mimetas B.V., Nortis Inc., Tissuse Gmbh, Organovo Holdings, Inc., and Hesperos Inc.